Monday, January 21, 2008

Isogenis: No Transplantation Rejection

Isogenis is focused upon novel immune modulating therapeutics for the treatment of immune disorders, genetic diseases, and transplant tolerance. A number of animal veto effect exploitation model transplantation systems have been developed for: pancreatic islet, liver, and heart transplantations, and have subsequently validated that their approaches have permanently protected tissues from rejection.

Current foci of product development include:

  1. Supressing Hybrid Antibodies - Engineered human antibody fragments coupled with human CD8 proteins to induce the veto effect and prevent transplant rejection.
  2. Viral Vectors - Engineered viruses that deliver the CD8 gene to induce transplant tolerance.
  3. Genetic Disease Therapeutics - Vectors developed to deliver genes repairing a genetic defect while simultaneously using veto technology to protect the gene product from rejection.
Efforts have now turned to the demonstration of proof-of-principle in large animal models. To aid in this effort a number of collaborations with the University of Minnesota and the University of Pittsburgh have been established.

So what exactly is the veto effect? It is a phenomenon that happens when CD8 protein expressed on the surface of a T cell recognizes another CD8 protein on the target cell. When this CD8 is recognized, the cytotoxic T Lymphocyte begins apoptosis. The immunological response is “vetoed” for this particular cell, but the immune system still functions normally.

***Update*** Be sure to get your vote in for the CLSDF Readers Company of the Year Award. ONLY TWO WEEKS remain to cast your ballot! Voting ends on 31 January.

If you enjoyed this post get free email or RSS updates (here).

No comments: